The contraceptive drugs market would grow at a CAGR of 5.85% over the predicted time frame. The market is expected to increase in value from US$ 16.25 Bn in 2022 to US$ 25.6 Bn in 2030.
The on contraceptive
drugs Market, which provides a business strategy, research & development
activities, concise outline of the market valuation, valuable insights
pertaining to market share, size, supply chain analysis, competitive landscape
and regional proliferation of this industry.
Download
Free Sample@ https://www.precedenceresearch.com/sample/1753
Report Scope of the Contraceptive Drugs Market
| Report Coverage | Details |
| Market Size by 2030 | USD 25.6 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 5.85% |
| Largest Market | North America |
| Fastest Growing Market | Asia-Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Product, Distribution Channel, Age Group, Geography |
A recent
report provides crucial insights along with application based and forecast
information in the Global Contraceptive drugs Market. The report provides a
comprehensive analysis of key factors that are expected to drive the growth of
this market. This study also provides a detailed overview of the opportunities
along with the current trends observed in the Contraceptive drugs market.
A
quantitative analysis of the industry is compiled for a period of 10 years in
order to assist players to grow in the market. Insights on specific revenue
figures generated are also given in the report, along with projected revenue at
the end of the forecast period.
Companies
and Manufacturers Covered
The study
covers key players operating in the market along with prime schemes and
strategies implemented by each player to hold high positions in the industry.
Such a tough vendor landscape provides a competitive outlook of the industry,
consequently existing as a key insight. These insights were thoroughly analysed
and prime business strategies and products that offer high revenue generation
capacities were identified. Key players of the global Contraceptive drugs
market are included as given below:
Contraceptive drugs Market Key Players
- Church & Dwight Co., Inc.
- Reckitt Benckiser Group Plc
- Veru, Inc.
- Organon Group of Companies
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
- The Cooper Companies, Inc.
- Mayer Laboratories, Inc.
- Agile Therapeutics
- TherapeuticsmMD, Inc.
- Bayer Ag
- Afaxys, Inc.
- Mithra Pharmaceuticals
- Abbvie
Market Segments
- Oral
- Pills
- Intrauterine Devices (IUD)
- Hormonal IUD
- Nonhormonal IUD
- Condoms
- Male Condoms
- Female Condoms
- Vaginal Ring
- Subdermal Implants
- Injectable
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Clinics
- Online Channel
- Public Channel & NGOs
- Others
By Age Group
- 15–24 years
- 25–34 years
- 35–44 years
- Above 44 years
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Report Objectives
- To define, describe, and forecast the global contraceptive
drugs market based on product, and region
- To provide detailed information regarding the major
factors influencing the growth of the market (drivers, opportunities, and
industry-specific challenges)
- To strategically analyze micromarkets1 with respect to
individual growth trends, future prospects, and contributions to the total
market
- To analyze opportunities in the market for stakeholders
and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to
four main regions—North America,
Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively
analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as
acquisitions, expansions, new product launches, and partnerships in the contraceptive
drugs market
Table of Content
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Contraceptive Drugs Market
5.1. COVID-19 Landscape: Contraceptive Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Contraceptive Drugs Market, By Product
8.1. Contraceptive Drugs Market, by Product, 2022-2030
8.1.1 Oral
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Lead Acid
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Intrauterine Devices (IUD)
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Condoms
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Vaginal Ring
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Subdermal Implants
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Injectable
8.1.7.1. Market Revenue and Forecast (2017-2030)
8.1.8. Others
8.1.8.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Contraceptive Drugs Market, By Distribution Channel
9.1. Contraceptive Drugs Market, by Distribution Channel, 2022-2030
9.1.1. Hospital Pharmacy
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Retail Pharmacy
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Clinics
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Online Channel
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Public Channel & NGOs
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Contraceptive Drugs Market, By Age Group
10.1. Contraceptive Drugs Market, by Age Group, 2022-2030
10.1.1. 15–24 years
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. 25–34 years
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. 35–44 years
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Above 44 years
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Contraceptive Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2017-2030)
11.1.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.4.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.4.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.4.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.4.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.4.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Age Group (2017-2030)
Chapter 12. Company Profiles
12.1. Church & Dwight Co., Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Reckitt Benckiser Group Plc
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Veru, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Organon Group of Companies
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Pfizer, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Teva Pharmaceutical Industries Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. The Cooper Companies, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Mayer Laboratories, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Agile Therapeutics
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. TherapeuticsmMD, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments